Search

Displaying results 8581 - 8590 of 10000 in total
  1. Drug

    LY-2584702

    go.drugbank.com/drugs/DB12690
    Investigational

    LY2584702 has been used in trials studying the treatment of Cancer, Advanced Cancer, Renal Cell Carcinoma, Metastases, Neoplasm, and Neuroendocrine Tumors, among others.

    Categories: Ribosomal Protein S6 Kinases, 70-kDa, antagonists & inhibitors, Heterocyclic Compounds, 1-Ring
  2. Drug

    Ibalizumab

    go.drugbank.com/drugs/DB12698
    ApprovedInvestigational

    Ibalizumab (also known as _ibalizumab-uiyk_ and formerly known as TNX-355) is a monoclonal antibody that binds to CD4 receptors on the surface of CD4-positive cells, preventing HIV particle entry into … In October 2022, the FDA approved the administration of Trogarzo (ibalizumab-uiyk) by intravenous push, allowing for a faster drug administration.[L43443,L43448]

    Categories: HIV 1 Post-attachment Fusion Inhibitors, Human Immunodeficiency Virus 1 Post-attachment Fusion Inhibitor
  3. Drug

    Spiradoline

    go.drugbank.com/drugs/DB12704
    Investigational

    Spiradoline has been investigated for the basic science of Bipolar Depression.

    Categories: Heterocyclic Compounds, 1-Ring
  4. Drug

    TTX-MC138

    go.drugbank.com/drugs/DB18628
    Investigational

    TTX-MC138 is an antisense oligonucleotide targeting miR-10b.[L48335] It is under investigation for the treatment of various metastatic cancers.

  5. Drug

    CYNK-101

    go.drugbank.com/drugs/DB18637
    Investigational

    CYNK-101 is an allogeneic human placental hematopoietic stem cell-derived natural killer (NK) cell therapy product that is genetically modified to express a variant of CD16 (CD16VP).

    Synonyms: allogeneic human placental hematopoietic stem cell derived natural killer (NK) cell therapy product that is genetically modified to express a variant of CD16 (CD16VP)
  6. Drug

    ALLO-605

    go.drugbank.com/drugs/DB18641
    Investigational

    ALLO-605 is an allogeneic turbo chimeric antigen receptor (Turbocar) T Cell therapy targeting B Cell maturation antigen (BCMA).

  7. Drug

    ATIR101

    go.drugbank.com/drugs/DB18650
    Investigational

    ATIR101 is a haploidentical, naïve cell-enriched T-cell therapy.

  8. Drug

    TUM012

    go.drugbank.com/drugs/DB18652
    Investigational

    TUM012 is a synthetic polymer PEG conjugated to a phospholipid anchor (2-dipalmitoyl-sn-glycerol-3-phosphatidylethanolamine)

  9. Drug

    ssCART-19 cells

    go.drugbank.com/drugs/DB18653
    Investigational

    ssCART-19 cells consist of autologous anti-CD19 Chimeric Antigen Receptors (CAR)-T cells expressing a short hairpin RNA (shRNA) against interleukin-6 (IL-6).

    Synonyms: autologous anti-CD19 Chimeric Antigen Receptors (CAR)-T cells expressing a short hairpin RNA (shRNA) against interleukin-6 (IL-6) (also termed ssCART-19 cells)
  10. Drug

    BBT-877

    go.drugbank.com/drugs/DB18668
    Investigational

    BBT-877 is an autotaxin enzyme inhibitor being investigated for the treatment of fibrotic diseases, such as idiopathic pulmonary fibrosis.

    Categories: Heterocyclic Compounds, 1-Ring